UY34388A - "5,7-IMIDAZO[1,2-c]PIRIMIDINAS SUSTITUIDAS" - Google Patents

"5,7-IMIDAZO[1,2-c]PIRIMIDINAS SUSTITUIDAS"

Info

Publication number
UY34388A
UY34388A UY0001034388A UY34388A UY34388A UY 34388 A UY34388 A UY 34388A UY 0001034388 A UY0001034388 A UY 0001034388A UY 34388 A UY34388 A UY 34388A UY 34388 A UY34388 A UY 34388A
Authority
UY
Uruguay
Prior art keywords
pyrimidins
imidazo
substituted
comorbidities
neoplasms
Prior art date
Application number
UY0001034388A
Other languages
English (en)
Inventor
Mark Laurence Boys
Erik James Hicken
Mark C Munson
C Todd Eary
Bruno P Hache
Robert D Groneberg
Darren M Harvey
Christopher F Kraser
Laird Ellen
Ren Li
John E Robinson
Laurence E Burgess
David A Moreno
Steven T Schlacter
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of UY34388A publication Critical patent/UY34388A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compuestos de Fórmula I, y estereoisómeros y sales y solvatos farmacéuticamente aceptables de estos, donde R1, R2, R3, R4, R5, R6, X1 y X2 tienen los significados que se proporcionan en la memoria descriptiva, son inhibidores de una o más cinasas JAK y son útiles en el tratamiento de enfermedades autoinmunitarias, enfermedades inflamatorias, rechazo de órganos, tejidos y células transplantadas, así como neoplasias y trastornos hematológicos y sus comorbilidades.
UY0001034388A 2011-10-12 2012-10-11 "5,7-IMIDAZO[1,2-c]PIRIMIDINAS SUSTITUIDAS" UY34388A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161546426P 2011-10-12 2011-10-12

Publications (1)

Publication Number Publication Date
UY34388A true UY34388A (es) 2014-04-30

Family

ID=47071473

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034388A UY34388A (es) 2011-10-12 2012-10-11 "5,7-IMIDAZO[1,2-c]PIRIMIDINAS SUSTITUIDAS"

Country Status (19)

Country Link
US (1) US20140228349A1 (es)
EP (1) EP2766368A1 (es)
JP (1) JP2014528475A (es)
KR (1) KR20140076619A (es)
CN (1) CN103987713A (es)
AR (1) AR088304A1 (es)
AU (1) AU2012323399A1 (es)
BR (1) BR112014008865A2 (es)
CA (1) CA2851623A1 (es)
CL (1) CL2014000931A1 (es)
CO (1) CO6950483A2 (es)
CR (1) CR20140216A (es)
IL (1) IL231903A0 (es)
MX (1) MX2014004473A (es)
RU (1) RU2014118954A (es)
SG (1) SG11201401342VA (es)
TW (1) TW201326173A (es)
UY (1) UY34388A (es)
WO (1) WO2013055645A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2634185T3 (en) 2012-03-02 2016-03-21 Sareum Ltd Tyk2 kinase inhibitors
BR112016003348B1 (pt) 2013-08-21 2023-03-07 Alios Biopharma, Inc Compostos antivirais ou sais farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e seus usos
CN105793245B (zh) * 2013-09-03 2018-03-20 萨勒姆有限公司 药物化合物
EP3227297B1 (en) * 2014-12-05 2021-01-20 Array Biopharma, Inc. 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors
HUE064003T2 (hu) 2015-01-20 2024-02-28 Wuxi Fortune Pharmaceutical Co Ltd JAK-gátló
AU2016254385B2 (en) * 2015-04-29 2018-05-10 Wuxi Fortune Pharmaceutical Co., Ltd JAK inhibitors
PT3305788T (pt) 2015-05-29 2020-09-25 Wuxi Fortune Pharmaceutical Co Ltd Inibidor da janus cinase
PT3419978T (pt) * 2016-02-24 2020-06-01 Pfizer Derivados de pirazolo[1,5-a]pirazin-4-ilo como inibidores de jak
GB201617871D0 (en) 2016-10-21 2016-12-07 Sareum Limited Pharmaceutical compounds
EP3668858A1 (en) * 2017-08-14 2020-06-24 Pfizer Inc Pyrazolo[1,5-a]pyrazin-4-yl and related derivatives
WO2019233434A1 (zh) * 2018-06-06 2019-12-12 杭州澳津生物医药技术有限公司 一种吡唑嘧啶衍生物及其用途和药物组合物
TW202028209A (zh) * 2018-09-27 2020-08-01 大陸商重慶複創醫藥研究有限公司 作為RET激酶抑制劑的取代的咪唑[1,2-a]吡啶和[1,2,4]三唑[1,5-a]吡啶化合物
AU2019373221B2 (en) 2018-10-31 2022-05-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having HPK1 inhibitory activity
SG11202103839UA (en) 2018-10-31 2021-05-28 Gilead Sciences Inc Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
CN111320624B (zh) * 2018-12-14 2023-05-12 中国医药研究开发中心有限公司 三唑并吡啶类和咪唑并吡啶类化合物及其制备方法和医药用途
AU2020256720B2 (en) * 2019-04-12 2022-09-01 PrimeGene (Beijing) Co. Ltd. Pyrazolopyrazine derived compounds, pharmaceutical composition and use thereof
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
CN111039963B (zh) * 2019-12-31 2021-03-19 卓和药业集团有限公司 Wxfl10203614水溶性类似物及其合成方法
WO2021173476A1 (en) * 2020-02-24 2021-09-02 The Trustees Of Columbia University In The City Of New York Compounds, pharmaceutical formulations, and methods for treatment of cancer
EP3944859A1 (en) 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
AU2021377891A1 (en) * 2020-11-13 2023-07-06 Biogen Ma Inc. Pyrazolo[1,5-a]pyrazine derivatives as btk inhibitors
AR125588A1 (es) 2021-03-04 2023-08-02 Lilly Co Eli Compuestos inhibidores de fgfr3

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5682799A (en) 1998-08-21 2000-03-14 Parker Hughes Institute Quinazoline derivatives
JP2001302667A (ja) * 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
MY159449A (en) * 2005-12-13 2017-01-13 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
JP5572388B2 (ja) * 2006-11-22 2014-08-13 インサイト・コーポレイション キナーゼ阻害剤としてのイミダゾトリアジンおよびイミダゾピリミジン
DE102007012645A1 (de) * 2007-03-16 2008-09-18 Bayer Healthcare Ag Substituierte Imidazo- und Triazolopyrimidine
CL2008001709A1 (es) * 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
EP2558468B1 (en) * 2010-04-14 2015-04-01 Array Biopharma, Inc. 5, 7-substituted-imidazo [1,2-c] pyrimidines as inhibitors of jak kinases

Also Published As

Publication number Publication date
IL231903A0 (en) 2014-05-28
MX2014004473A (es) 2015-04-14
TW201326173A (zh) 2013-07-01
CO6950483A2 (es) 2014-05-20
BR112014008865A2 (pt) 2017-04-25
KR20140076619A (ko) 2014-06-20
EP2766368A1 (en) 2014-08-20
WO2013055645A1 (en) 2013-04-18
CL2014000931A1 (es) 2014-08-29
CN103987713A (zh) 2014-08-13
AU2012323399A1 (en) 2014-05-29
SG11201401342VA (en) 2014-09-26
US20140228349A1 (en) 2014-08-14
CA2851623A1 (en) 2013-04-18
JP2014528475A (ja) 2014-10-27
AR088304A1 (es) 2014-05-21
CR20140216A (es) 2014-08-21
RU2014118954A (ru) 2015-11-20

Similar Documents

Publication Publication Date Title
UY34388A (es) "5,7-IMIDAZO[1,2-c]PIRIMIDINAS SUSTITUIDAS"
CR20120572A (es) 5,7-SUSTITUIDO-IMIDAZO [1, 2-c]PIRIMIDINAS
CR20170309A (es) Pirazolo [1,5-a] pirazinas 4,6-sustituidas como inhibidores de janus cinasas
CY1122266T1 (el) Ενωσεις 3-αμινοκυκλοαλκυλιου ως ror-gamma-t αναστολεις και χρησεις αυτων
CR11690A (es) Pirazolo (3,4-b) piridinas como inhibidores de raf
DOP2018000227A (es) Inhibidores de bromodominios
ECSP10010510A (es) Compuestos del inhibidor de raf y métodos de uso de los mismos
CR20120410A (es) Pirrolidina-2-carboxamidas sustituidas
DOP2014000152A (es) Inhibidores de bromodominios
EA202090291A2 (ru) Производные бипиразола в качестве ингибиторов jak
CO6361910A2 (es) Pirrolidina-2-carboxamidas sustituidas
NI201000119A (es) Compuestos de 3h-[1,2,3]triazolo[4,5-d] pirimidina, su uso como inhibidores de cinasa mtor y cinasa pi3, y sus síntesis.
CR20120591A (es) Derivados de aminopirimidina como moduladores de la lrrk2
EA201390766A1 (ru) БЕНЗОКСАЗЕПИНЫ КАК ИНГИБИТОРЫ PI3K/mTOR И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ И ПОЛУЧЕНИЯ
TR201909849T4 (tr) Btk etkinliği inhibitörleri olarak heteroaril piridon ve aza-piridon bileşikleri.
CR11803A (es) Pirrolopiridinas como inhibidores de cinasa
CR11757A (es) Compuestos de triazina como inhibidores mtor y quinasa pi3
GT201200242A (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6
PA8779101A1 (es) "compuestos tricíclicos como inhibidores de metaloproteinasas matriciales"
EA201301301A1 (ru) Производные тиазола
EA201200087A1 (ru) 2-карбоксамиды циклоаминомочевин, которые являются ингибиторами pi3k
EA201390755A1 (ru) БЕНЗОКСАЗЕПИНЫ КАК ИНГИБИТОРЫ PI3K/mTOR И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ И ПРОИЗВОДСТВА
ECSP12011678A (es) Metilpirrolopirimidincarboxamidas
EA201390757A1 (ru) БЕНЗОКСАЗЕПИНЫ КАК ИНГИБИТОРЫ PI3K/mTOR И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ И ПРОИЗВОДСТВА
CO6592046A2 (es) 5-alquinil pirimidas y su uso como inhibidores de quinasa

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20201020